VENOLEN CREAM 40G 2%

VENOLEN 2% CREMA

active ingredients

100 g cream contain: 2 g of Troxerutina. Excipients with known effects: contains methyl and propile p-hydroxybenzoates and glycol propylene. For the full list of excipients, see paragraph 6.1.

Excellent

Ascorbic acid, polyglycolic ester of fatty acids, glycol propylene, p-hydroxybenzoate methyl, p-hydroxybenzoate propylene, purified water.

Therapeutic indications

Symptoms attributable to venous failure; states of capillary fragility.

Contraindications

Hypersensitivity to the active ingredient or any of the excipients listed in paragraph 6.1. Generally contraindicated in pregnancy and nursing (see paragraph 4.6).

Population

Population: Apply the cream 2-3 times a day.

Conservation

This medicine does not require any special condition of conservation.

Warnings

It is advisable to stop the administration of the drug during the menstrual period. Venolen 2% cream contains methyl and p-hydroxybenzoate propile, which can cause allergic reactions (also delayed). This medicine contains 4000 mg of glycol propylene per 40 g cream tube.

Interactions

No known interaction effects.

Effects

Undesirable effects are classified by systems and organs and by frequency. The frequencies are defined as: Very common (≥1/10), Common (≥1/100, gastrointestinal pathologies. Rare: gastrointestinal disorder (lieve). Vascular diseases. Rare: vasodilation (of the face). The prolonged use of topical products can give rise to awareness-raising phenomena. Where this occurs, treatment should be suspended and appropriate treatment should be established. Reporting of suspicious adverse reactions. The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address www.agenziafarmaco.gov.it/content/come-segnalare-una-sospetta-reazione-avversa.

Overdosing

No overdose cases have been reported.

The safety of the drug during pregnancy has not been determined, therefore it is not appropriate to administer the product during pregnancy.

Source: Farmadati